NCT02228928

Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain

Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in the Management of Peripheral Neuropathic Pain ; Early Phase II, Multi-center, Randomized, and Semi-double Blind Controlled Clinical Trial

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Samyang Biopharmaceuticals Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The efficacy and safety of the low concentration \[0.65% (50 µg/cm2) and 1.25% (100 µg/cm2)\] capsaicin patches and compared them to conventional 0.075% capsaicin cream and placebo patch in patients suffering from peripheral neuropathy

Conditions

• Peripheral Nerve Injury
• Postherpetic Neuralgia

Interventions

Type	Name	Description
DRUG	CAPNP, 50 ug/cm2 capsaicin patch
DRUG	CAPNP, 100 ug/cm2 capsaicin patch
DRUG	0.075% capsaicin cream
OTHER	Placebo patch

Timeline

• Start date: 2009-02-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2014-08-29
• Last updated: 2017-05-01

Locations

1 site across 1 country: South Korea